![]() |
市場調查報告書
商品編碼
1499523
下一代乳癌診斷和篩檢市場:按產品、診斷技術、篩檢技術、應用和最終用戶 - 2024-2030 年全球預測Next-Generation Breast Cancer Diagnostic & Screening Market by Product, Diagnostic Technology, Screening Technology, Application, End User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
下一代乳癌診斷和篩檢市場規模預計到2023年為228.1億美元,2024年達到251.2億美元,預計到2030年將達到471.1億美元,複合年成長率為10.91%。
下一代乳癌診斷和篩檢技術代表了乳癌檢測和診斷方式的模式轉移,與傳統方法相比,提供了更準確、更有效率、更侵入性的方法。這些先進技術,包括數位乳房X光攝影、3D乳房X光攝影(斷層合成)、自動乳房超音波和分子乳房攝影,利用高階影像和基因組分析來及早發現可治療的乳癌。推動這些新診斷工具的關鍵因素包括全球乳癌流行、對早期檢測的認知和支持的提高、影像技術的進步以及個人化醫療的推動。儘管它們很重要,但這些下一代技術面臨實際挑戰,例如高成本、資源匱乏環境中的獲取機會有限以及過度診斷可能導致不必要的治療。為了解決這些限制,我們需要透過創新和規模來降低成本,改善醫療基礎設施,並制定更細緻的篩檢通訊協定,以平衡早期檢測和過度診斷的風險,並需要共同努力來實施。整合人工智慧以提高診斷準確性,開發攜帶式篩檢設備以提高獲取率,以及基因組分析的持續發展以預測乳癌風險並相應調整篩檢策略,我們期望擴大下一代乳癌領域。診斷和篩檢。
主要市場統計 | |
---|---|
基準年[2023] | 228.1億美元 |
預測年份 [2024] | 251.2億美元 |
預測年份 [2030] | 471.1億美元 |
複合年成長率(%) | 10.91% |
區域洞察
先進的乳癌診斷技術(包括基因檢測和液態切片)的使用在美洲相當普及,特別是在美國和加拿大,這得益於對醫療保健技術的大量投資和我支持的乳癌早期檢測計劃的強大框架。該地區擁有專門從事癌症診斷的領先公司,為創新篩檢解決方案的研究、開發和商業化提供了有利的環境。在亞太地區,由於中國、日本和印度等國家的意識增強和醫療基礎設施的改善,下一代診斷技術的引入正在迅速進展。本地和全球公司正在積極擴大業務並客製化產品以滿足特定人群的需求。 EMEA(歐洲、中東和非洲)是一個多元化的地區,西歐國家在有利的衛生政策和強大的公共和私人衛生系統的支持下,先進診斷工具的採用率很高。然而,在東歐、中東和非洲,提高乳癌篩檢率和逐步引入下一代診斷方法的努力開始產生影響,他們面臨著獲取和負擔能力問題。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在下一代乳癌診斷和篩檢市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對下一代乳癌診斷和篩檢市場中供應商的當前狀態進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭力的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在下一代乳癌診斷和篩檢市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[190 Pages Report] The Next-Generation Breast Cancer Diagnostic & Screening Market size was estimated at USD 22.81 billion in 2023 and expected to reach USD 25.12 billion in 2024, at a CAGR 10.91% to reach USD 47.11 billion by 2030.
Next-generation breast cancer diagnostic & screening technologies represent a paradigm shift in how breast cancer is detected and diagnosed, offering more precise, efficient, and less invasive methods compared to traditional modalities. These advanced technologies, including digital mammography, 3D mammography (tomosynthesis), automated breast ultrasound, and molecular breast imaging, leverage high-end imaging and genomic profiling to identify breast cancers at an early stage when they are most treatable. Major factors driving the adoption of these novel diagnostic tools include the prevalence of breast cancer globally, increased awareness and advocacy for early detection, advancements in imaging technology, and a push toward personalized medicine. Despite their significant importance, these next-generation technologies face utility challenges such as high costs, limited access in low-resource settings, and the potential for overdiagnosis leading to unnecessary treatments. Addressing these restraints requires concerted efforts to reduce costs through technological innovations and scale, improving healthcare infrastructure, and implementing more nuanced screening protocols to balance early detection with the risk of overdiagnosis. Integration of artificial intelligence to improve diagnostic accuracy, the development of portable screening devices to increase access, and the continuous evolution of genomic profiling to predict breast cancer risk and tailor screening strategies accordingly are expected to expand the next-generation breast cancer diagnostic & screening space in the coming years.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 22.81 billion |
Estimated Year [2024] | USD 25.12 billion |
Forecast Year [2030] | USD 47.11 billion |
CAGR (%) | 10.91% |
Regional Insights
In the Americas, particularly in the United States and Canada, the use of advanced breast cancer diagnostics, including genetic testing and liquid biopsies, is quite prevalent, supported by substantial investments in healthcare technology and a robust framework for early breast cancer detection programs. The region is home to major companies specializing in oncology diagnostics, fostering an environment conducive to the research, development, and commercialization of innovative screening solutions. The APAC region is experiencing rapid growth in the adoption of next-generation diagnostics, driven by increasing awareness and improving healthcare infrastructures in countries such as China, Japan, and India. Local and global players are actively expanding their presence, tailoring products to meet specific population needs. EMEA presents a varied picture, with Western European countries showcasing high adoption rates of advanced diagnostic tools underpinned by favorable healthcare policies and strong public-private healthcare systems. However, Eastern Europe, the Middle East, and Africa face accessibility and affordability issues, though initiatives aimed at improving breast cancer screening rates and the gradual entry of next-gen diagnostics are beginning to make an impact.
Market Insights
The market dynamics represent an ever-changing landscape of the Next-Generation Breast Cancer Diagnostic & Screening Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Next-Generation Breast Cancer Diagnostic & Screening Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Next-Generation Breast Cancer Diagnostic & Screening Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
GE HealthCare Releases MyBreastAI Suite to Support Clinicians in Accelerating Breast Cancer Detection
GE Healthcare unveiled its MyBreastAI Suite, a ground-breaking artificial intelligence (AI) platform designed to revolutionize breast cancer detection and enhance clinical workflows. This innovative suite integrates three sophisticated AI applications from iCAD: ProFound AI for DBT, SecondLook for 2D Mammography, and PowerLook Density Assessment, all aimed at supporting early breast cancer detection and improving outcomes for patients. [Published On: 2023-11-27]
Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations
Exact Sciences Corp. has announced strategic collaborations with the Broad Institute of MIT and Harvard and Baylor Scott White, aiming to revolutionize patient care by enhancing access to advanced genomic data. Through these partnerships, Exact Sciences is set to leverage the Broad Institute's groundbreaking Minor Allele Enriched Sequencing Through Recognition Oligonucleotides (MAESTRO) technology. This technology offers an ultra-sensitive approach for the detection of molecular residual disease, employing minimal sequencing while maximizing bioinformatic analysis to identify thousands of patient-specific mutations. [Published On: 2023-06-21]
Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets
Pfizer and Thermo Fisher Scientific Inc. have forged a groundbreaking partnership aimed at revolutionizing cancer care by expanding access to next-generation sequencing (NGS) for lung and breast cancer diagnostics in over 30 countries across Latin America, Africa, the Middle East, and Asia. This strategic alliance seeks to counteract the limitations and inaccessibility that have historically marred the provision of advanced genomic testing in these regions. By leveraging Thermo Fisher's expertise in NGS technology, the collaboration is aimed to establish local laboratories equipped with the necessary infrastructure and professional training to uphold stringent industry standards. [Published On: 2023-05-09]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Next-Generation Breast Cancer Diagnostic & Screening Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Next-Generation Breast Cancer Diagnostic & Screening Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agendia Inc., Agilent Technologies, Inc., ARTIVION INC., Becton, Dickinson and Company, Benitec Biopharma Ltd, BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Centogene N.V., Danaher Corporation, Epic Sciences, Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, GE HealthCare Technologies, Inc., Hologic, Inc., Illumina, Inc., Invivoscribe, Inc., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Merck & Co., Inc., Myriad Genetics, Inc., Novartis AG, Pfizer Inc., QIAGEN N.V., Siemens Healthineers AG, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage